Masseter Botox — injecting botulinum toxin into the main chewing muscle to slim the lower face — is one of the most requested off-label neuromodulator treatments in aesthetic practice. It is also one of the most misunderstood. Patients often expect a simple, reversible jawline contouring procedure. What they get is a real change in how their face looks, how their bite feels, and in some cases, whether their lower face sags over time.
This article covers the anatomy, the evidence, the functional tradeoffs, and the specific complications that cause patients to regret the procedure — and when it works well.
The masseter: anatomy that matters
The masseter is a thick, quadrilateral muscle on each side of the jaw. It originates from the zygomatic arch (cheekbone) and inserts on the angle and ramus of the mandible (lower jaw). Its primary function is elevating the mandible — closing the jaw during chewing. It is one of the strongest muscles in the body relative to its size.
The masseter has two heads: a superficial portion that runs obliquely downward and backward, and a deep portion that runs more vertically. Both contribute to jaw closure. The muscle is innervated by the mandibular division of the trigeminal nerve (V3).
When the masseter is overactive or hypertrophied — from chronic clenching, bruxism (teeth grinding), gum chewing, or genetics — it creates a broad, square lower-face shape. This is particularly common in East Asian populations, where masseteric hypertrophy is a frequent aesthetic concern and masseter Botox is among the most commonly requested procedures.
What masseter Botox actually does
Botulinum toxin type A injected into the masseter blocks acetylcholine release at the neuromuscular junction, reducing the muscle's ability to contract. With reduced activity, the muscle undergoes disuse atrophy — it shrinks. The result is a narrower, more tapered lower face.
A 2025 prospective study published in BMC Oral Health used 3D facial scanning to measure volume changes after masseter Botox. The study found statistically significant reductions in lower face volume at 4, 8, and 12 weeks post-injection. Per-side reductions ranged from approximately 2,500–3,100 mm³ at 4 weeks to 3,600–6,800 mm³ at 8 weeks. Combined (bilateral) volume reductions reached over 10,000 mm³ at 4 weeks and over 13,000 mm³ at 12 weeks. Patient-reported outcomes measured via the FACE-Q scale showed improved satisfaction with facial appearance throughout the study period.
This is consistent with clinical experience: masseter Botox produces visible slimming, the effect peaks around 8–12 weeks, and the muscle gradually regains size over 4–6 months as nerve signaling recovers.
The off-label reality
Masseter Botox is not FDA-approved. Botox Cosmetic (onabotulinumtoxinA) is approved for glabellar lines, lateral canthal lines, forehead lines, and platysmal bands. Its use in the masseter muscle for facial contouring or TMJ-related symptoms is off-label.
This does not mean the treatment is experimental. Off-label use is legal, common, and supported by a growing body of peer-reviewed literature. But it does mean the same level of FDA-reviewed safety and dosing data that exists for the approved cosmetic indications does not exist for this application. The long-term effects of repeated masseter injections — particularly on bone — are still being studied.
Dosing in clinical practice typically ranges from 20–30 units per side (40–60 units total), administered at 2–3 injection points per masseter. There is no FDA-established dose for this indication; these ranges come from clinical experience and published studies.
Functional changes: what happens to your bite
The masseter's job is chewing. Weakening it means reducing bite force. This is not a theoretical risk — it is an expected effect.
A 2025 study in PMC measured bite force changes after botulinum toxin injection into different combinations of masticatory muscles. In the masseter-only group (the most relevant to aesthetic use), maximum bite force decreased by approximately 150 N at 1 and 2 weeks post-injection — a moderate effect size (Cohen's d = 0.65). By 1 month, bite force was trending toward baseline and was no longer statistically significantly reduced after adjustment.
What this means in practice: most patients notice a reduction in chewing strength for the first 2–4 weeks, particularly with hard or tough foods. For the majority, this is mild and not distressing. The BMC Oral Health study found that participants consistently reported "normal chewing ability" at all follow-up points, despite measurable volume reduction. But a subset of patients — particularly those who eat hard, chewy, or crunchy foods regularly, or who have dental conditions that already compromise chewing — find the functional change more bothersome than expected.
Bite force recovers because the masseter is not permanently damaged. As the toxin wears off, the muscle regains strength. But during each 4–6 month treatment cycle, there is a window of reduced chewing capacity.
Smile asymmetry: the most visible complication
The most commonly reported concerning side effect of masseter Botox is smile asymmetry — a crooked or uneven smile that develops when the toxin diffuses beyond the masseter into adjacent muscles, particularly the buccinator or zygomaticus major.
A 2025 clinical training review from Derma Medical identified the mechanism: injections placed too far anteriorly (forward) or too far superiorly (high) in the masseter can affect muscles responsible for elevating the corner of the mouth. The result is asymmetric smiling, where one side of the mouth does not elevate as fully as the other.
Smile asymmetry from masseter Botox is:
- Temporary. It resolves as the toxin wears off, typically within 4–8 weeks.
- Preventable. Correct injection technique requires placing the injection in the posterior-inferior portion of the masseter, at least 1 cm anterior to the posterior border of the mandible and below the level of the earlobe. Injection points should stay within the "safe zone" — the bulk of the muscle belly, away from the zygomatic arch anteriorly and the parotid gland.
- More common with inexperienced injectors. The masseter's proximity to multiple expression muscles makes injection placement precision critical.
Other less common complications include cheek hollowing (from diffusion into the buccinator), difficulty with mouth opening, and paradoxical bulging — where parts of the muscle shrink unevenly, creating a wavy or lumpy jawline contour.
The jowl question: can masseter Botox cause sagging?
This is the complication patients rarely hear about during consultation and the one most likely to cause long-term regret.
The masseter muscle provides structural support to the soft tissues of the lower face. When it shrinks significantly — either from a single high-dose session or from repeated treatments over years — the overlying skin and fat lose some of their underlying scaffolding. The result can be:
- Hollowing of the pre-auricular area (the space in front of the ear), creating a gaunt or drawn appearance.
- Early or worsened jowling as lower-cheek tissue loses support and descends.
- A "sagging" lower face that looks older rather than more refined.
Multiple clinical sources, including The Luxe Room and The Skin Company, identify this as a known risk of overtreatment. The Luxe Room notes that hollow pre-auricular area or early jowling occurs when "the muscle shrinks too much and no longer supports the tissue around it." Correction typically requires discontinuing masseter injections and allowing the muscle to rebound.
This risk is dose- and patient-dependent. Patients with thin faces, minimal subcutaneous fat, or early signs of skin laxity are more vulnerable. Patients with genuinely hypertrophied masseters and thicker soft-tissue envelopes are less likely to experience sagging.
The concern is amplified by the trend toward combining masseter Botox with "traptox" (trapezius Botox) for comprehensive upper-body slimming. Simultaneously reducing structural volume in the jaw and shoulder area can create a cascade of tissue descent that neither treatment alone would produce.
Asymmetry and one-sided treatment
Some patients have unilateral masseter hypertrophy — one side is larger, often from chronic unilateral chewing or sleeping position. In these cases, a provider may treat only the larger side or dose the sides differently to rebalance the face.
This is a high-skill intervention. Overcorrecting the larger side can swing asymmetry in the opposite direction. Undercorrecting means the imbalance persists. And treating the dominant side can unmask an asymmetric bite, creating dental issues that were previously masked by the stronger muscle.
Most experienced injectors treat both sides even when asymmetry exists, adjusting the dose to favor the larger side while still reducing the smaller side proportionally.
Bone changes: the evidence that is still developing
A 2017 longitudinal study published in the Korean Journal of Orthodontics (Lee et al.) found that repeated botulinum toxin injections into the masseter muscle produced statistically significant bone loss in the mandible. The study compared single-injection and double-injection groups using cone-beam computed tomography (CBCT). The double-injection group showed measurable thinning of mandibular bone at 6 months.
The TMJ Association has flagged this research as concerning, noting that the findings are consistent with animal studies showing dramatic bone quality and volume changes in the mandibular condyle after even a single injection. A larger follow-up study was planned to compare 50 TMD patients who received multiple masseter Botox sessions with 50 who had not, using CBCT imaging.
This evidence is not yet conclusive, and it does not mean masseter Botox is unsafe. But it does mean the long-term skeletal effects of repeated injections are not fully characterized. Patients considering years of masseter Botox should be aware that bone remodeling is a plausible and under-studied risk.
When masseter Botox works well
Despite the risks, masseter Botox is a good treatment for the right patient. It works best when:
- The patient has genuinely hypertrophied masseters (palpable enlargement at clenching, confirmed by the provider).
- The lower face is broad or square specifically because of muscle bulk, not fat, bone structure, or skin laxity.
- The patient understands that bite force will be temporarily reduced and accepts that tradeoff.
- The provider uses conservative initial doses and reassesses at 4–6 weeks before adding more.
- The patient does not have pre-existing lower-face sagging, jowling, or thin subcutaneous tissue that would be worsened by volume loss.
When patients regret it
Regret most commonly traces to:
- Unexpected smile asymmetry from poor injection placement.
- Sagging or jowling from overtreatment, especially in patients who were not good candidates for significant volume reduction.
- Chewing difficulty that is more disruptive than expected, particularly in patients who eat hard or chewy foods regularly.
- A face shape that looked good in photos but feels wrong in person — the "over-V-shaped" result where the jawline narrows too aggressively and looks artificial.
- Dental changes — bite shifts, difficulty with specific foods, or jaw joint discomfort from altered muscle balance.
Most of these are reversible (the toxin wears off), but the wait can be months, and the psychological impact of an asymmetric or sagging face during that window is significant.
What to ask before treatment
- "Is my wide jaw caused by muscle, fat, or bone?" If the provider cannot answer this clearly, they have not done an adequate assessment.
- "How many units per side do you plan to use, and why?" An experienced provider will explain their reasoning based on muscle palpation and facial analysis, not default to a standard dose.
- "What is your approach to avoiding smile asymmetry?" The answer should include reference to injection placement in the posterior-inferior safe zone.
- "What happens if my lower face starts to sag?" A good provider will have a plan — usually discontinuing treatment and allowing the muscle to recover, possibly supplemented by soft-tissue support if needed.
- "Will you check my bite before and after?" Not all providers do this, but it is a reasonable question for a treatment that weakens the primary chewing muscle.
Sources
- Sawadsopanont N, et al. Facial volume reduction and masticatory function after masseter botulinum toxin injection: a prospective study. BMC Oral Health. 2025;25:1595. https://pmc.ncbi.nlm.nih.gov/articles/PMC12512921/
- PMC. "The Effective Way of Botulinum Toxin Injection to Reduce Bite Force: Preliminary Study." 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12567990/
- Lee HJ, et al. Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: A longitudinal study. Korean J Orthod. 2017;47(4):222-228. (Summarized by The TMJ Association: https://tmj.org/repeated-injections-of-botox-in-the-masseter-muscle-a-longitudinal-study/)
- Drugs.com. "Masseter Botox for Jaw Slimming: Benefits, Cost, Side Effects & Results." Medically reviewed Dec 2025: https://www.drugs.com/medical-answers/what-masseter-botox-3577094/
- Derma Medical. "Masseter Botox & Smile Asymmetry: Causes, Risks, and How to Avoid It." 2025: https://dermamedical.co.uk/masseter-botox-smile-asymmetry-risks-prevention/
- StatPearls. "Anatomy, Head and Neck, Masseter Muscle." NCBI Bookshelf: https://www.ncbi.nlm.nih.gov/books/NBK539869/
- BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information. Allergan/AbbVie: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103000s5306lbl.pdf
